Peer-Reviewed Publication
Neurology2026;107(5):e218407.September 8, 2026Journal Article
Analysis of Interindividual Lesion Progression Variability in Adult Cerebral Adrenoleukodystrophy.
Markus Ponleitner1,2,3, Julia Lier1, Luc Bracoud4, Eda G Kabak5, Robert Thompson6, Haley G McLaughlin6, Alessandro Delmonte4, Thomas Cajgfinger4, Lisa Schäfer1, Carolin Eva Awißus1, Isabelle Weinhofer7, Paulus S Rommer2,3, Johannes Berger7, Daniel J Loes8, Florian S Eichler6, Marc Engelen5, Wolfgang Köhler1, Caroline G Bergner1
1Department of Neurology, Leipzig University Medical Center, Germany.
2Department of Neurology, Medical University of Vienna, Austria.
3Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna, Austria.
4Clario Inc., Lyon, France.
5Department of Neurology and Pediatric Neurology, Emma Children's Hospital, Amsterdam UMC, Amsterdam Leukodystrophy Center, Amsterdam University Medical Center, Amsterdam, the Netherlands.
6Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.
7Department Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, Austria; and.
8Suburban Radiologic Consultants Ltd., Minneapolis, MN.
Abstract
BACKGROUND AND OBJECTIVES: Cerebral adrenoleukodystrophy (cALD), the most severe clinical phenotype of X-linked adrenoleukodystrophy (X-ALD), is characterized by rapidly progressive, inflammatory destruction of the cerebral white matter. In adult patients, therapeutic options are limited to hematopoietic stem cell transplantation, which carries substantial treatment-related risks, necessitating ca…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans